These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27049733)

  • 1. Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety.
    Heldmann F; Baraliakos X; Kiltz U; Brandt J; van der Horst-Bruinsma IE; Landewé R; Sieper J; Burmester GR; van den Bosch F; de Vlam K; Gaston H; Gruenke M; Witt M; Appelboom T; Emery P; Dougados M; Leirisalo-Repo M; Breban M; Braun J
    Clin Exp Rheumatol; 2016; 34(2):184-90. PubMed ID: 27049733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome.
    Baraliakos X; Listing J; Fritz C; Haibel H; Alten R; Burmester GR; Krause A; Schewe S; Schneider M; Sörensen H; Schmidt R; Sieper J; Braun J
    Rheumatology (Oxford); 2011 Sep; 50(9):1690-9. PubMed ID: 21672969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
    Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
    Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
    Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
    Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study.
    Moreno M; Gratacós J; Torrente-Segarra V; Sanmarti R; Morlà R; Pontes C; Llop M; Juanola X;
    Arthritis Res Ther; 2019 Apr; 21(1):88. PubMed ID: 30953541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
    Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
    Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of ultrasound to monitor Achilles enthesitis in patients with ankylosing spondylitis during TNF-a antagonist therapy.
    Wang CH; Feng Y; Ren Z; Yang X; Jia JF; Rong MY; Li XY; Wu ZB
    Clin Rheumatol; 2015 Jun; 34(6):1073-8. PubMed ID: 25896532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study.
    Saougou I; Markatseli TE; Voulgari PV; Drosos AA
    Joint Bone Spine; 2010 Jul; 77(4):325-9. PubMed ID: 20452801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety.
    Maksymowych WP; Jhangri GS; Lambert RG; Mallon C; Buenviaje H; Pedrycz E; Luongo R; Russell AS
    J Rheumatol; 2002 May; 29(5):959-65. PubMed ID: 12022358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors.
    Shimabuco AY; Gonçalves CR; Moraes JCB; Waisberg MG; Ribeiro ACM; Sampaio-Barros PD; Goldenstein-Schainberg C; Bonfa E; Saad CGS
    Adv Rheumatol; 2018 Dec; 58(1):40. PubMed ID: 30657103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis.
    Wang R; Dasgupta A; Ward MM
    J Rheumatol; 2018 Apr; 45(4):481-490. PubMed ID: 29335342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
    Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
    Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years.
    Poddubnyy D; Fedorova A; Listing J; Haibel H; Baraliakos X; Braun J; Sieper J
    J Rheumatol; 2016 Dec; 43(12):2142-2148. PubMed ID: 27803139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].
    Brandt J; Westhoff G; Rudwaleit M; Listing J; Zink A; Braun J; Sieper J
    Z Rheumatol; 2003 Jun; 62(3):264-73. PubMed ID: 12827403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis.
    Rahman P; Choquette D; Bensen WG; Khraishi M; Chow A; Zummer M; Shaikh S; Sheriff M; Dixit S; Sholter D; Psaradellis E; Sampalis JS; Letourneau V; Lehman AJ; Nantel F; Rampakakis E; Otawa S; Shawi M
    BMJ Open; 2016 Apr; 6(4):e009661. PubMed ID: 27048632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab.
    Lorenzin M; Ortolan A; Frallonardo P; Oliviero F; Punzi L; Ramonda R
    BMC Musculoskelet Disord; 2015 Jul; 16():166. PubMed ID: 26205000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab.
    Heldmann F; Brandt J; van der Horst-Bruinsma IE; Landewe R; Sieper J; Burmester GR; van den Bosch F; de Vlam K; Geusens P; Gaston H; Schewe S; Appelboom T; Emery P; Dougados M; Leirisalo-Repo M; Breban M; Listing J; Braun J
    Clin Exp Rheumatol; 2011; 29(4):672-80. PubMed ID: 21906431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
    Braun J; Brandt J; Listing J; Zink A; Alten R; Burmester G; Golder W; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Reddig J; Sieper J
    Arthritis Rheum; 2003 Aug; 48(8):2224-33. PubMed ID: 12905476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.